Sign In
Buy CARM
$0.0001
+0 (+0%)
At Close: Jun 03, 2026
Carisma Therapeutics Announces Expansion of Its Scientific Advisory Board
07:30am, Tuesday, 06'th Aug 2024
Company appoints renowned key opinion leaders in liver fibrosis, Scott Friedman, MD, and Ira Tabas, MD, PhD PHILADELPHIA , Aug. 6, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Ca
Carisma Therapeutics Announces Changes to its Board of Directors
07:30am, Monday, 01'st Jul 2024
Appointment of David Scadden, M.D. and Marella Thorell Resignation of Regina Hodits and Björn Odlander PHILADELPHIA , July 1, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carism
Development Candidate targets Glypican-3 for the treatment of solid tumors, including hepatocellular carcinoma Nomination triggers a $2 million milestone payment to Carisma PHILADELPHIA , June 27, 202
Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors
07:30am, Tuesday, 25'th Jun 2024
Fast Track designation highlights potential for CT-0525 to address unmet need for patients with solid tumors Initial Phase 1 data expected by year-end 2024 PHILADELPHIA , June 25, 2024 /PRNewswire/ --
Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum
07:30am, Tuesday, 25'th Jun 2024
PHILADELPHIA , June 25, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing in
Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders
04:30pm, Thursday, 13'th Jun 2024
Meeting will be reconvened on Friday, June 14, 2024 at 10:00 a.m. Eastern Time PHILADELPHIA , June 13, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a c
Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference
07:30am, Thursday, 30'th May 2024
PHILADELPHIA , May 30, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing inn
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte
07:30am, Thursday, 16'th May 2024
CT-0525 is the first CAR-Monocyte to be evaluated in humans in the solid tumor setting Initial data expected by year-end 2024 PHILADELPHIA , May 16, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Na
Carisma Therapeutics Inc. (CARM) Reports Q1 Loss, Misses Revenue Estimates
09:36am, Thursday, 09'th May 2024
Carisma Therapeutics Inc. (CARM) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $1.93 per share a year ago.
Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
07:30am, Thursday, 09'th May 2024
Announced CT-0525 as lead product candidate for anti-HER2 program; initial data expected by year-end 2024 Presented preclinical proof of concept data in liver fibrosis at ASGCT; expects to nominate a
Novel anti-fibrotic engineered macrophage therapy reduced liver fibrosis in preclinical models Development candidate nomination expected in the first quarter of 2025 PHILADELPHIA , May 8, 2024 /PRNews
Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference
07:30am, Monday, 06'th May 2024
PHILADELPHIA , May 6, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing inno
Carisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
11:05am, Thursday, 02'nd May 2024
CARISMA THERAP (CARM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer
07:30am, Thursday, 02'nd May 2024
Industry veteran with expertise in oncology and immuno-oncology and a strong track record of advancing programs through clinical development PHILADELPHIA , May 2, 2024 /PRNewswire/ -- Carisma Therape
Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
04:35pm, Monday, 22'nd Apr 2024
Preclinical data highlights the potential of engineered macrophage cell therapy as a treatment for liver and lung fibrosis Novel Redirected Soluble Modulator technology has demonstrated the potential
